Low-molecular-weight heparin (dalteparin) demonstrated a weaker effect on rat bone metabolism compared with heparin

Japanese Journal of Pharmacology

Volumn 74, Issue 1, 1997, Pages 59-68

  Nishiyama, Masahiko ^a   Itoh, Fumiaki ^a   Ujiie, Arao ^a  

^a KISSEI PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Bone metabolism; Dalteparin sodium; Heparin; Osteopenia

Indexed keywords

ALBUMIN; ALKALINE PHOSPHATASE; CALCIUM; DALTEPARIN; GLOBULIN; HEPARIN; OSTEOCALCIN; PHOSPHORUS; PROTEIN; TRANSFORMING GROWTH FACTOR BETA1;

ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL EXPERIMENT; ARTICLE; BODY WEIGHT; BONE GROWTH; BONE MASS; BONE METABOLISM; BONE MINERAL; CALCIUM BLOOD LEVEL; CONTROLLED STUDY; DOSE RESPONSE; FEMUR FRACTURE; INTRAVENOUS DRUG ADMINISTRATION; MALE; MORPHOMETRICS; NONHUMAN; OSSIFICATION; OSTEOLYSIS; PHOSPHATE BLOOD LEVEL; PROTEIN BLOOD LEVEL; RAT; TIBIA;

EID: 0030918053     PISSN: 00215198     EISSN: None     Source Type: Journal    
DOI: 10.1254/jjp.74.59     Document Type: Article

References (40)

1. Griffith GC., Nichols G, Asher JD and Flanagan B: Heparin osteoporosis. JAMA 193, 85-88 (1965)
2. Jaffe MD and Willis PW III: Multiple fractures associated with long-term sodium heparin therapy. JAMA 193, 152-154 (1965)
3. Swiet MD, Ward PD, Fidler J, Horsman A, Katz D, Letsky E, Peacock M and Wise PH: Prolonged heparin therapy in pregnancy causes bone demineralization. Br J Obstet Gynaecol 90, 1129-1134 (1983)
4. Avioli LV: Heparin-induced osteopenia: an appraisal. Adv Exp Med Biol 52, 375-387 (1975)
5. Tarquini B, Benvenuti M, Brandi ML, Cecchettin M and Ianes A: Short-term effects of heparin on urine hydroxyproline in the elderly. Curr Ther Res 46, 755-761 (1989)
6. Mutoh S, Takeshita N, Yoshino T and Yamaguchi I: Characterization of heparin-induced osteopenia in rats. Endocrinology 133, 2743-2748 (1993)
7. Hamano S, Kinukawa M, Komatsu H, Ikeda S and Sakuragawa N: Effects of low molecular weight heparin (FR-860) on coagulative and fibrinolytic activities. Folia Pharmacol Jpn 94, 243-249 (1989) (Abstr in English)
8. ®) in patients with venous thromboembolism and contraindications to coumarin. Thromb Haemost 71, 7-11 (1994)
9. Yamazaki I and Yamaguchi H: Characteristics of an ovariectomized osteopenic rat model. J Bone Miner Res 4, 13-22 (1989)
10. Igarashi C and Ezawa I: Effects of whey calcium and lactulose on the strength of bone in ovariectomized osteoporosis model rats. Pharmacometrics 42, 245-253 (1991) (Abstr in English)
11. Andersson LO, Barrowcliffe TW, Holmer E, Johnson EA and Söderström G: Molecular weight dependency of the heparin; Potentiated inhibition of thrombin and activated factor X. Effect of heparin neutralization in plasma. Thromb Res 15, 531-541 (1979)
12. Sakuragawa N and Takahashi K: Comparative studies on properties of unfractionated and low molecular weight heparin. Semin Thromb Hemost 16, Supp 5-11 (1990)
13. Chowdhury MH, Hamada C and Dempster DW: Effects of heparin on osteoclast activity. J Bone Miner Res. 7, 771-777 (1992)
14. Yasumura S, Aloia JF, Gundberg CM, Yeh J, Vaswani AN, Yuen K, Monte AFL, Ellis K and Cohn SH: Serum osteocalcin and total body calcium in normal pre-and postmenopausal women and post-menopausal osteoporolic patients. J Clin Endocrinol Metab 64, 681-685 (1987)
15. Hurley MM, Gronowicz G, Kream BE and Raisz LG: Effect of heparin on bone formation in cultured fetal rat calvaria. Calcif Tissue Int 46, 183-188 (1990)
16. Eeckhout Y and Delaisse JM: The role of collagenase in bone resorption; An overview. Pathol Biol 36, 1139-1146 (1988)
17. Lin KH, Hino H, Maeda S, Inagaki H, Airat JV and Saito T: Albumin synthesis by rat hepatocytes cultured on collagen gels is sustained specifically by heparin. Exp Cell Res 219, 717-721 (1995)
18. Canalis E, Centrella M and McCarthy T: Effects of basic fibroblast growth factor on bone formation in vitro. J Clin Invest 81, 1572-1577 (1988)
19. Lam LH, Silbert JE and Rosenberg RD: The separation of active and inactive forms of heparin. Biochem Biophys Res Commun 69, 570-577 (1976)
20. Hock M, Bjork I, Hopwood J and Lindahl U: Anticoagulant activity of heparin; Separation of high-activity and low-activity heparin species by affinity chromatography on immobilized antithrombin. FEBS Lett 66, 90-93 (1984)
21. Shimotori T and Sakuragawa N: Comparative studies of heparin cofactor activity toward antithrombin III and heparin cofactor II, and antithrombin III affinity between low molecular weight heparin and unfractionated heparin. Semin Thromb Hemost 16, Supp 71-76 (1990)
22. Jawed F, Jeanine MW, Debra H, Adrienne R and Erwin C: Chemical and biological heterogeneity in low molecular weight heparins; Implications for clinical use and standardization. Semin Thromb Hemost 15, 440-463 (1989)
23. Petitou M: Chemical synthesis of heparin. In Heparin, Edited by Lane DA and Lindahl U, pp 65-79, Edward Arnold, Division of Hodder and Stoughton, London (1989)
24. Mätzsch T, Bergqvist D, Hedner U, Nilsson B and Østergaard P: Effects of low molecular weight heparin and unfragmented heparin on induction of osteoporosis in rats. Thromb Res 63, 505-509 (1990)
25. Eriksson BI, Söderberg K, Widlund L, Wandeli B, Tengborn L and Risberg B: A comparative study of three low-molecular weight heparins (LMWH) and unfractionated heparin (UH) in healthy volunteers. Thromb Haemost 73, 398-401 (1995)
26. Wright TC, Pukac LA, Castellot JJ, Karnovsky MJ, Levine RA, Kimpark HY and Campisi J: Heparin suppresses the induction of c-fos and c-myc mRNA in murine fibroblasts by selective inhibition of a protein kinase C-dependent pathway. Proc Natl Acad Sci USA 86, 3199-3203 (1989)
27. Lippman MM and Mathews MB: Heparins; Varying effects on cell proliferation in vitro and lack of correlation with anticoagulant activity. Fed Proc 36, 55-59 (1977)
28. Shaughnessy SG, Young E, Deschamps P and Hirsh J: The effects of low molecular weight and standard heparin on calcium loss from fetal rat calvaria. Blood 86, 1368-1373 (1995)
29. Nagai H, Tsukuda R and Mayahara H: Effects of basic fibroblast growth factor (bFGF) on bone formation in growing rats. Bone 16, 367-373 (1995)
30. Kato Y and Iwamoto M: Fibroblast growth factor is an inhibitor of chondrocyte terminal differentiation. J Biol Chem 265, 5903-5909 (1990)
31. Yayon A, Klagsbrun M, Esko JD, Leder P and Ornitz DM: Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor. Cell 64, 841-848 (1991)
32. Ruoslahti E and Yamaguchi Y: Proteoglycans as modulators of growth factor activities. Cell 64, 867-869 (1991)
33. Klagsbrun M: The affinity of fibroblast growth factor (FGFs) for heparin; FGF-heparin sulfate interactions in cells and extra-cellular matrix. Curr Opin Cell Biol 222, 857-863 (1990)
34. Ornitz DM, Yayon A, Flanagan JG, Svahn CM, Levi E and Leder P: Heparin is required for cell-free binding of basic fibroblast growth factor to a soluble receptor and for mitogenesis in whole cells. Mol Cell Biol 12, 240-247 (1992)
35. Dalton BA, Mcfarland CD, Underwood PA and Steele JG: Role of the heparin binding domain of fibronectin in attachment and spreading of human bone-derived cells. J Cell Sci 108, 2083-2092 (1995)
36. Ruppert R, Hoffmann E and Sebald W: Human bone morphogenetic protein 2 contains a heparin-binding site which modifies its biological activity. Eur J Biochem 237, 295-302 (1996)
37. Jackson RL, Busch SJ and Cardin AD: Glycosaminoglycans; molecular properties, protein interactions, and role in physiological processes. Physiol Rev 71, 481-539 (1991)
38. Yang L and Yang YC: Heparin inhibits the expression of interleukin-11 and granulocyte-macrophage colony-stimulating factor in primate bone marrow stromal fibroblasts through mRNA destabilization. Blood 86, 2526-2533 (1995)
39. Koller M, Schoch U, Buchmann P, Largiadèr F, Felten A and Frick PG: Low-molecular-weight heparin (Kabi-2165) as thromboprophylaxis in elective visceral surgery. A randomized, double-blind study versus unfractionated heparin. Thromb Res 56, 243-246 (1986)
40. Caen JP: A randomized double-blind study between a low-molecular-weight heparin Kabi 2165 and standard heparin in the prevention of deep vein thrombosis in general surgery. A French multicenter trial. Thromb Res 59, 216-220 (1988)